Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts Details-
Title Grant Type Focus Area Country Application Due Date Real World Evidence on the Impact of Early and Appropriate Use of Aztreonam-Avibactam (ATM-AVI)Release Date:Research Inflammation & Immunology Brazil, Chile, India, Italy, South Africa, Spain, United Kingdom Guideline Concordant Care and New Data for Patients with MIBC through la/mUCEducation Oncology USA Clinical Research Studies of Atirmociclib in HR+/HER2- and/or HER2+ Breast CancerRelease Date:Research Oncology Australia, Brazil, Canada, China, France, Germany, Italy, Japan, Korea, Mexico, Spain, Taiwan, USA, United Kingdom Quality Improvement Interventions to Enhance the Care of Patients Infected by MBL-CRE or S. maltophiliaRelease Date:Quality Improvement Inflammation & Immunology Australia, Chile, India, Italy, Spain, United Kingdom Advancing Real-World Evidence in Idiopathic Inflammatory Myopathies Through a German Disease RegistryRelease Date:Research Inflammation & Immunology Germany Real-World Evidence on Clinical Outcomes with ATM-AVI in Adult Patients with Stenotrophomonas maltophilia InfectionsRelease Date:Research Inflammation & Immunology China Real-World Evidence on Clinical Outcomes with Aztreonam-Avibactam (ATM-AVI) in Adult Patients with Limited Treatment OptionsRelease Date:Research Inflammation & Immunology China Tissue Penetration and Correlation with Clinical Outcomes of ATM-AVI in Adult Patients with Limited Treatment OptionsRelease Date:Research Inflammation & Immunology China Advancing Multidisciplinary Care in HemophiliaRelease Date:Quality Improvement Rare Disease China BCMA BsAb Educational Initiatives in 2L+ Relapsed/Refractory Multiple MyelomaRelease Date:Education Oncology USA -
Title Grant Type Focus Area Country Application Due Date Alopecia Areata (Global)Release Date:Research Inflammation & Immunology USA Advancing Health Literacy in The Republic of IrelandRelease Date:Education Support for the Professions Ireland Education to Improve Antimicrobial Resistance (AMR) ManagementRelease Date:Partner: Japanese Society of ChemotherapyEducation Hospital Japan Education on the Appropriate Diagnosis and Treatment of Overactive Bladder or Neurogenic BladderRelease Date:Education Internal Medicine Japan Promote the Streamline and Optimization of Healthcare System to Improve Regional DisparitiesRelease Date:Partner: Japan Association for Development of Community MedicineQuality Improvement Support for the Professions Japan Novel Digital Diagnostic Approaches in Acromegaly and Sickle Cell DiseaseRelease Date:Research Rare Disease USA Establishing Regional Medical Care Coordination System for Detailed examination of the Causes of Heart FailureRelease Date:Quality Improvement Rare Disease Japan Improving Knowledge and Capability to Communicate Information on the Latest Hemophilia TreatmentsRelease Date:Education Rare Disease Japan Ulcerative Colitis (UC) ResearchRelease Date:Research Inflammation & Immunology Albania, Andorra, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Holy See (Vatican City State), Hungary, Iceland, Ireland, Israel, Italy, Korea, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, The Former Yugoslav, Malta, Moldova, Republic of, Monaco, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, San Marino, Slovakia (Slovak Republic), Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom Quality Improvement Grants to Support Development of Cardiac Amyloid CentersRelease Date:Quality Improvement Rare Disease USA Quantifying the Socio-Economic Burden of Disease for Dermatology Patients and CaregiversRelease Date:Research Inflammation & Immunology Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Japan, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia (Slovak Republic), Spain, Sweden, Switzerland, United Kingdom Evidence-informed treatment decisions in chronic inflammatory disordersRelease Date:Quality Improvement Inflammation & Immunology Australia